MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

cencora-logo-svg

Cencora, Inc. (COR)

cencora-logo-svg

Cencora, Inc. (COR)

|||

Cash Flow Overview

Change in Cash
$628,695K
Free Cash flow
$2,428,021K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Borrowings under revolving and s...
    • Accounts payable
    • Net income
    • Others
Negative Cash Flow Breakdown
    • Repayments under revolving and s...
    • Purchases of common stock
    • Inventories
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
776,667
1,629,528
566,126
-333,071
Depreciation, including amounts charged to cost of goods sold
154,410
142,302
135,247
133,728
Amortization, including amounts charged to interest expense
123,018
120,675
129,024
130,270
Provision for credit losses
11,721
-4,885
13
17,792
Provision for deferred income taxes
54,884
178,407
14,362
55,389
Share-based compensation expense
28,733
28,002
66,054
25,943
Lifo credit
-94,304
-210,030
-77,562
-56,962
Trkiye highly inflationary impact
15,724
10,474
8,723
12,660
Impairment of assets, including goodwill
0
0
249,498
837,378
Adjustments to rca and oneoncology equity units
55,167
55,445
-32,783
-
Adjustments-Contingent Consideration Equity Units
-
-
-
121,666
Remeasurement gain related to oneoncology acquisition (note 2)
0
1,086,612
-
-
Adjustments-Contingent Consideration Predefined Business Objective
-
-
-
19,550
(gain) loss on divestiture of businesses
17,247
0
0
0
Gain on remeasurement of equity investment
-6,000
0
10,501
-16,501
Gain on divestiture of equity investment
0
-
-
0
Gain on sale of assets
-1,282
234
35,816
-
Other, net
13,800
5,681
-6,726
3,594
Accounts receivable
445,946
-522,077
830,752
945,803
Inventories
886,857
-3,399,637
3,519,839
319,548
Prepaid expenses and other assets
-107,734
-68,490
14,386
63,957
Accounts payable
2,827,267
-3,501,753
1,307,868
3,755,256
Accrued expenses
36,138
70,971
-328,365
-21,131
Income taxes payable and other liabilities
17,363
-78,174
-13,726
-86,278
Long-term accrued litigation liability
-103,894
-
-
-404,102
Net cash provided by operating activities
2,654,060
1,338,639
-2,305,169
3,133,417
Capital expenditures
226,039
165,618
119,376
249,812
Cost of acquired companies, net of cash acquired
41,660
4,712,350
219,686
91,410
Proceeds from sale of assets
2,043
717
43,057
-
Proceeds from divestiture of a business
25,000
-
-
-
Cost of equity investments
9,269
8,500
10,710
2,450
Non-customer note receivable
2,813
20,626
0
34,814
Other, net
-6,963
9,776
-7,400
-21,732
Net cash used in investing activities
-240,149
-4,874,901
-299,315
-321,940
Senior notes and loan borrowings
39,328
4,540,483
107,720
0
Senior notes and loan repayments
719,646
217,784
131,709
517,203
Borrowings under revolving and securitization credit facilities
12,884,288
47,212,956
23,791,590
45,980,788
Repayments under revolving and securitization credit facilities
12,852,175
47,424,106
23,501,389
46,045,822
Purchases of common stock
1,000,052
0
0
0
Exercises of stock options
-
-
7,598
6,520
Cash dividends on common stock
116,589
117,456
126,516
107,512
Employee tax withholdings related to restricted share vesting
138
7,035
98,151
109
Other, net
-2,841
-893
-5,939
-444
Net cash provided by financing activities
-1,767,825
3,978,567
43,204
-683,782
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
-10,694
9,751
-24,576
-8,472
Decrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for sale
635,392
-2,133,800
-
-
Less increase in cash classified within assets held for sale
-6,697
-24,487
-
-
Decrease in cash, cash equivalents, and restricted cash
628,695
427,569
-2,585,856
2,119,223
Cash, cash equivalents, and restricted cash at beginning of period
1,808,693
1,808,693
4,394,549
3,394,974
Cash, cash equivalents, and restricted cash at end of period
2,864,957
2,236,262
1,808,693
4,394,549
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Accounts payable$2,827,267K (365.33%↑ Y/Y)Net income$776,667K (12.60%↑ Y/Y)Depreciation, includingamounts charged to cost...$154,410K (18.45%↑ Y/Y)Amortization, includingamounts charged to...$123,018K (-4.35%↓ Y/Y)Prepaid expenses andother assets-$107,734K (24.95%↑ Y/Y)Adjustments to rca andoneoncology equity units$55,167K (47.27%↑ Y/Y)Provision for deferredincome taxes$54,884K (429.48%↑ Y/Y)Accrued expenses$36,138K (-79.09%↓ Y/Y)Share-based compensationexpense$28,733K (23.93%↑ Y/Y)Income taxes payableand other...$17,363K (-4.88%↓ Y/Y)Trkiye highlyinflationary impact$15,724K (-6.40%↓ Y/Y)Provision for creditlosses$11,721K (-64.65%↓ Y/Y)Gain onremeasurement of equity...-$6,000K (-122.01%↓ Y/Y)Gain on sale of assets-$1,282K Net cash provided byoperating activities$2,654,060K (2329.41%↑ Y/Y)Canceled cashflow$1,562,048K Decrease in cash, cashequivalents, and restricted...$635,392K Canceled cashflow$2,018,668K Inventories$886,857K (-9.88%↓ Y/Y)Accounts receivable$445,946K (-41.29%↓ Y/Y)Long-term accruedlitigation liability-$103,894K Lifo credit-$94,304K (-81.15%↓ Y/Y)(gain) loss ondivestiture of businesses$17,247K Other, net$13,800K (-65.30%↓ Y/Y)Borrowings under revolvingand securitization...$12,884,288K (-69.70%↓ Y/Y)Senior notes and loanborrowings$39,328K (-96.69%↓ Y/Y)Proceeds fromdivestiture of a business$25,000K Other, net-$6,963K (-12.31%↓ Y/Y)Non-customer note receivable$2,813K Proceeds from sale ofassets$2,043K Decrease in cash, cashequivalents, and restricted...$628,695K (549.75%↑ Y/Y)Canceled cashflow$6,697K Net cash provided byfinancing activities-$1,767,825K (-920.40%↓ Y/Y)Net cash used ininvesting activities-$240,149K (-2.33%↓ Y/Y)Effect of exchange ratechanges on cash, cash...-$10,694K (-259.14%↓ Y/Y)Canceled cashflow$12,923,616K Canceled cashflow$36,819K Less increase in cashclassified within assets...-$6,697K Repayments under revolvingand securitization...$12,852,175K (-70.23%↓ Y/Y)Capital expenditures$226,039K (23.37%↑ Y/Y)Cost of acquiredcompanies, net of cash...$41,660K (-26.21%↓ Y/Y)Purchases of common stock$1,000,052K Senior notes and loanrepayments$719,646K (234.96%↑ Y/Y)Cash dividends oncommon stock$116,589K (8.46%↑ Y/Y)Other, net-$2,841K (53.77%↑ Y/Y)Employee taxwithholdings related to...$138K (18.97%↑ Y/Y)Cost of equityinvestments$9,269K (662.25%↑ Y/Y)